Carboplatin Media Statement

MAKE A DONATION

Carboplatin Media Statement

5 April 2016

The hospital apologises deeply and unreservedly to the patients and families affected by this matter. We are sorry you’ve had to go through this; and we are sorry for letting you down in this way.

In fact, we apologise to all our cancer patients at the Sydney hospital – including those not directly affected or involved in the dosage issue – because many would still have found this matter a source of anxiety and concern.

Finally, we apologise to the public, who rightfully have high expectations of the hospitals that care for them and their loved ones.

We now have two priorities: to support the patients affected and their families, and to make sure this doesn’t happen again.

We have already begun contacting all the patients involved and their families – as we’ve done previously – to update them on the Cancer Institute’s review and its findings.

Importantly, we have engaged Professor Robert Thomas OAM – Chief Advisor on Cancer to the Victorian Government – to oversee the hospital’s implementation of the review’s recommendations.

Professor Thomas is one of Australia’s most respected cancer surgeons. He will provide a public report on our progress at three, six and 12 months, so we can be judged on our performance.

It’s clear we have not lived up to the high standards we set ourselves.

We failed to appreciate the seriousness of the situation: early questions about the doctor’s dosage practice should have led to a formal examination.

Both our internal and external inquiries should have been more comprehensive and completed more quickly in order to begin talking with patients and their families sooner and with greater accuracy.

And while very early on we made the decision we wouldn’t contact patients about this matter until we had all the information at hand so as not to cause unnecessary distress, we now recognise this was a mistake and accept the review’s findings that we should have communicated with patients earlier.

We are working hard to ensure similar problems do not occur again.

During the course of the review we provided approximately 1400 separate documents to the review team. Many of our staff were interviewed or provided statements.

For over the past 18 months we’ve been making changes – independent of this matter – to strengthen governance within the hospital.

We have put in place a world-standard cancer electronic medication system that automatically updates new dosage protocols. If any clinician wants to prescribe medication outside the guidelines they must submit their request and explain their reasoning. Regular clinical audits will also ensure this is occurring.

Already, all cancer patients at St Vincent’s are treated and overseen by a multi-disciplinary team as per the review’s Statewide recommendations.

The hospital has established a new peak clinical governance committee – known as the Clinical Council – which brings together senior clinicians, consumers and executives in the planning and operations of St Vincent’s. And we have established a Cancer Services Advisory Council to oversee the implementation of the hospital’s new Cancer Services Plan.

We have also recently appointed a number of consumer advocates to key governance committees and departments, including the Clinical Governance Committee for Cancer Services.

Finally, in December 2015, our new head of Medical Oncology – a world-leader in his field – commenced with the hospital.

If you have concerns about the treatment you or a loved one has received or require further information relating to the off-dosing of Carboplatin, please call our toll free line 1800 901 922. The 1800 number will be operational from 8.30am – 8.30pm.

 

 

 

Dr Rachel Dear

IMG_5109bw-crop-smallMBBS (Hons 1) PhD FRACP
Staff specialist in Medical Oncology, The Kinghorn Cancer Centre

Conjoint lecturer UNSW and Senior Lecturer, Sydney Medical School, University of Sydney

 

Dr Rachel Dear is a medical oncologist at The Kinghorn Cancer Centre and St Vincent’s Hospital, Darlinghurst with interests in the diagnosis and management of breast and lung cancers, and neuro-oncology.

Rachel’s employment includes a fractional appointment as a staff specialist in medical oncology, as well as part-time senior lecturer at the Sydney Medical School, University of Sydney. She participates in the on call roster for all medical oncology patients, and takes part in the undergraduate, basic physician and advanced trainee education programs.

Background

Rachel Dear was awarded MBBS (first class honours) from the University of New South Wales in 2001 and subsequently undertook junior medical officer and basic physician’s training at St Vincent’s Hospital, Darlinghurst. This was followed by advanced medical oncology training at Westmead Hospital.  From 2008-2012 she completed a PhD titled “The potential of clinical trial registries to inform cancer care in Australia” from the Sydney Medical School at the University of Sydney. During her PhD she held a NSW Cancer Institute Research Scholar Award from 2009-2012. She has worked as a medical oncologist at the Mater Hospital, North Sydney from 2012-2014, where her clinical work focused on breast cancer. In her role as Senior Lecturer at the University of Sydney, Rachel has completed a Cochrane Systematic Review looking at the role of chemotherapy in metastatic breast cancer, and she is currently conducting a study examining the control arm of randomized breast cancer trials.

Rachel has been the coordinating investigator for several investigator-initiated Australian studies from 2008-2011. She completed the Australia and Asia-Pacific Clinical Oncology Research Development (ACORD) workshop in 2010, a Cochrane protocol development workshop in 2008, and was awarded the Clinical Oncological Society of Australia (COSA) Best of the Best Primary Care and Health Sciences poster and presentation in 2011. Rachel holds a number of memberships to professional bodies including COSA, MOGA, ANZBCTG, ALTG, and PoCOG.

Contact information
Phone: +61 2 9355 5655
Fax: +61 2 9355 5602
Email: Rachel.Dear@svha.org.au

Associate Professor Richard Gallagher

GALLAGHER_DR_RICHARD-150x150MBBS FRACS
Clinical Director, The Kinghorn Cancer Centre

Director Cancer Services, St Vincent’s Health Network Sydney
Director Head and Neck Service, St Vincent’s Health Network Sydney
Adjunct Associate Professor, University of Notre Dame, Australia

Richard is the Director of Cancer Services for the St Vincent’s Health Network, Sydney. He facilitates collaboration between researchers at the Garvan Institute and clinicians at St Vincent’s Hospital by bringing them together at The Kinghorn Cancer Centre. This maximises innovation in benchside to bedside research, ultimately delivering better outcomes for patients with cancer.

Richard is Australia’s leading transoral robotic surgeon (TORS) with a particular interest in the management of human papilloma virus (HPV) related oropharyngeal cancers.  He has worked at St Vincent’s Hospital as a Head and Neck Surgeon since 1998 and manages the care of hundreds of public and private cancer patients every year. He holds editorial positions with leading surgical journal publications and is fiercely committed to surgical education, training and mentoring.

Richard places enormous importance on the multi-disciplinary approach to patient care. He knows from firsthand experience how teamwork and collaboration can make a world of difference in the cancer patient journey.

Background

Richard is a graduate of the University of New South Wales and a Fellow of the Royal Australasian College of Surgeons. Following completion of his surgical training in Australia in 1995 he completed two fellowships; one year of Head & Neck Surgery at Princess Alexandra Hospital, Brisbane, and one year of Sinus and Skull Base Surgery at The University of Virginia, Charlottesville, VA, USA. He returned to Australia to commence his appointment at St Vincent’s Hospital, Sydney, where he established an annual Functional Endoscopic Sinus Surgery Course, as well as the St Vincent’s Hospital Indigenous Otolaryngology – Head & Neck Surgery Outreach Clinic at Pius X Aboriginal Corporation, Moree. In 2011 Richard trained in the United States in transoral robotic surgery (TORS) and introduced the technique to St Vincent’s and New South Wales. He is the Chair of the Board of Otolaryngology-Head and Neck Surgery at the Royal Australasian College of Surgeons and is also an Examiner for the College. Richard holds editorial positions with the Australian New Zealand Journal of Surgery and the Australian supplement of The Journal of Laryngology & Otology, and is an Adjunct Associate Professor at the University of Notre Dame, Australia. He is a Visiting Medical Officer at St Vincent’s Hospital and is active across the campus on a number of committees. Richard’s private practice is located at St Vincent’s Clinic where he specialises in benign and malignant head and neck surgery.

Appointments

Chair, Board of Otolaryngology – Head & Neck Surgery, Royal Australasian College of Surgeons

Examiner, Royal Australasian College of Surgeons

Specialty Editor, Australian New Zealand Journal of Surgery

Editorial Board, Australian Supplement of the Journal of Laryngology and Otology

Agency for Clinical Innovation Tracheostomy Care Guideline Implementation Steering Committee

The Kinghorn Cancer Centre Launches Online Virtual Tours

kinghorn2Following its recent participation in Sydney Living Museums’ Sydney Open event External Link, The Kinghorn Cancer Centre has once again opened its doors to the public – this time with a series of online virtual tours hosted on its website.

The tours allow website users to navigate through the ground floor and first floor of The Kinghorn Cancer Centre using Google Business View technology, enabling a similar experience to Google’s popular Street View service. They include access to the building’s reception and atrium area, Nelune Centre treatment areas, wellness centre and consultation areas.

Additional single shot 360° panoramas allow website users to see inside research facilities in the upper levels of the building, while a rooftop panorama affords a view of nearby St Vincent’s Hospital, along with Darlinghurst and Sydney’s CBD and harbour.

The Kinghorn Cancer Centre eNews Issue 13 – December 2014

Cancer Division news from Garvan

Some exciting news from the Garvan team in the Kinghorn Cancer Centre.

Garvan researchers ranked as top applicants for Cancer Institute NSW Fellowships

Dr Marina Pajic and Dr Mark Cowley from Garvan were awarded Cancer Institute NSW Fellowships this year, each ranked as top applicant in their category, a Career Development Fellowship and Early Career Fellowship respectively.

Mark Cowley is one of twenty researchers from various universities and research institutes across the State to receive an Early Career Fellowship. Marina Pajic is one of four researchers to receive a Career Development Fellowship.

Marina Pajic leads a research group with an interest in developing new ways to treat pancreatic cancer, the fourth leading cause of cancer death. The molecular make-up of pancreatic tumours varies greatly, with different combinations of thousands of genetic mutations possible. Some tumour subtypes can be targeted with known drugs.

Mark Cowley is a bioinformatics expert who will be combining his cancer genomics expertise with the expertise of colleagues who will create animal models of breast cancer. Mark will study tumour progression in those models by regularly extracting DNA from blood, sequencing the DNA, and running algorithms—which he will develop—to analyse the results.

Read More

Garvan researcher creates spectacular biomedical animation of pancreatic cancer

Three biomedical animations recently premiered at Melbourne’s Deakin Edge theatre in Federation Square, and are now available for television broadcast and online education.

The creators are three scientist-animators: Dr Kate Patterson from Garvan, Chris Hammang from CSIRO, and Dr Maja Divjak from Melbourne’s Walter and Eliza Hall Institute of Medical Research.

Called “VIZBIplus – Visualising the Future of Biomedicine”, the project is led jointly by Dr Kate Patterson, Dr Sean O’Donoghue from CSIRO and Garvan and Mr Drew Berry from the Walter and Eliza Hall Institute.

Kate Patterson’s animation shows that cancer is not a single disease. She highlights the role of the tumour suppressor protein p53, known as ‘the guardian of the cell’, in the formation of many cancer types.

“Mutated p53 is just one of thousands of mistakes that can occur in cancer,” said Kate.

“DNA sequencing and other new technologies now enable these mistakes to be detected in individual cancers. What’s really exciting is that different types of cancer can share some molecular mistakes which means treatments developed for one cancer could be used to treat another.”

View Dr Patterson’s video

Cancer services/care news from St Vincent’s

By Professor Allan Spigelman, Director, St Vincent’s Cancer and Immunology Program

Progress continued to be made in attaining our goal of realising “the promise of personalised innovative medicine for people affected with cancer” in the past year.

TKCC facilities were used by 22,636 patients, an increase of 8.5% when compared with pre-TKCC activity at St Vincent’s Hospital. There has been an even greater increase in the percentage of patients receiving chemotherapy, with 12% more patients treated in the TKCC Chemotherapy Suite (the Nelune Centre) than at St Vincent’s prior to the opening of TKCC. In addition, the St Vincent’s Hospital Hereditary Cancer Clinic in TKCC saw a 86% increase in new referrals. Further negotiations are in place to establish both the Wellness Centre and café on the ground floor level of TKCC.

The professional and social interaction between clinicians and researchers has gathered pace, with greater interaction between the two groups both at formal meetings and at combined social events. The design of TKCC facilitates interaction by collision, as well as by collusion; the tea rooms/refreshment stations being a focal point not just for water cooler chat but for discussions on breaking research news.

Acquisition of the latest gene sequencing equipment (the HiSeq X Ten Sequencing System) will allow whole human genome sequencing in TKCC at much reduced cost. The system is produced by American company Illumina Inc., whose CEO commented that ”we approached the Garvan Institute due to its strength in the analysis and interpretation of genomic data, and its close affiliation with St Vincent’s Hospital.” This state-of-the-art system, which exemplifies the translational research paradigm, whereby patients benefit rapidly from the close interaction between researchers and clinicians within TKCC, was purchased once again with the generous support of the Kinghorn Foundation. The new system will be used for large-scale research projects and for problem-dependent diagnostic purposes, including the routine analysis of cancer biopsies.

It was a pleasure to have been present at the conception, inception and implementation of our cancer centre. I welcome Professor David Thomas as incoming Director, TKCC, to the substantive post, commencing in mid-2014, and acknowledge the outstanding contribution of the late Professor Robert Sutherland in the planning for TKCC.

I thank all who have made TKCC a reality. As a result, we have a secure base in which our patients can be seen and treated in comfort, where our staff can work in spacious and modern conditions and where we can hasten the development of effective treatments and quality of life improvements for those who require our care.

Professor David Thomas Joins The Kinghorn Cancer Centre as Director

david-thomasFollowing the announcement last December of the appointment of Prof David Thomas as the new Director of The Kinghorn Cancer Centre, David has now commenced the role here.  In addition to this role, he will also serve as Head of the Garvan Institute of Medical Research’s Cancer Division, as well as leading a research laboratory (Genomic Cancer Medicine) there.

David joins The Kinghorn Cancer Centre from the Peter MacCallum Cancer Centre in Melbourne, where he headed the medical oncology program within the Sarcoma Service.  A National Health & Medical Research Council (NHMRC) Senior Research Fellow at the University of Melbourne, David has published over 100 peer-reviewed publications spanning basic, translational and clinical research, with a particular focus on the impact of genomics on cancer medicine.

His current research interests include how cancers evolve – mapping changes in cancer genomes at the chromosomal level – and understanding how the immune system sculpts tumour development.

He has a specific interest in rare cancers known as ‘sarcomas’, which particularly affect the young. They comprise 20% of childhood cancers and 10% of cancers in young adults, but only 1% of cancers overall. There are around 70 subtypes of sarcoma, each requiring different kinds of treatment, and therefore depending upon highly specialised multidisciplinary care.

“I am especially interested in liposarcomas and osteosarcomas, sarcomas that affect fat cells or bone, and that interest extends from genomic research within tumours, all the way through to clinical trial,” he explained.

David’s clinical achievements include leadership of the first trial of denosumab in the treatment of Giant Cell Tumour of bone, which was recently approved as standard of care by the US Food and Drug Administration. He leads several large-scale cancer cohorts, including the International Sarcoma Kindred Study, and Cancer2015, a genomic study of 10,000 newly diagnosed cancer patients in Victoria.

“The Cancer2015 program that I set up in Victoria is about bringing genomics into the field of clinical care. My plan is to implement a similar program in New South Wales, using the information drawn from the cohort to service the population of the State.”

“The Victorian and New South Wales programs should be interoperable, meaning they should be structured in such a way that the data can be brought together, creating more than the sum of its parts.”

“We need to think very carefully about how the knowledge we obtain can be used to intervene in human health – to assess cancer risk, for example, or to evaluate molecular targeted therapies.”

“It seems to me that the implications of genomic medicine are so broad that they go right to the fabric of how we fund health care. So we may as well get started trying to weave those elements together and form an evidence base that can drive the very large-scale investments that will be required to exploit our knowledge fully.”

David sees The Kinghorn Cancer Centre as the ideal place from which to start this process. “The centre forms a natural bridge between the superb basic science of the Garvan Institute and the clinical work of St Vincent’s Hospital and broader cancer community. My job is to fill it with people and ideas, so that knowledge becomes vision, which in turn translates into better health outcomes.”

Louise Lynagh

BSc (Hons) Biochemistry, MSc Human Nutrition, Graduate Certificate Genetic Counselling
Genetic Counsellor

 

Louise works alongside Professor Allan Spigelman, Consultant at St Vincent’s Hereditary Cancer Clinic. They work with patients and family members to assess the chance of there being an inherited predisposition to cancer in the family. Together they compose an extensive family tree, which is used to assess this risk.

Some families are then offered genetic testing with discussions around what this information will mean for themselves and their family members. The Clinic aims to find the particular genetic cause of cancer in each family. If this is found, unaffected family members can then be offered genetic testing to find out if they have inherited an increased risk of cancer. If so advice is offered on evidence based personalised strategies to reduce this risk.

The ethos of the Clinic is early detection or prevention of cancer by helping people to understand their risk of cancer and how to reduce it. The Clinic also facilitates rapid genetic testing for patients and their doctors who will use this information to make decisions about future treatments and surgeries. The team endeavours to supply a timely, high quality, equitable service and to contribute to ongoing research in the field.

The St Vincent’s Hereditary Cancer Clinic team has an interest in facilitating recruitment for anybody who is eligible and willing to participate in genetic research into their particular condition. The Clinic is also linked with the pancreatic cancer research team at the Garvan

Background

Louise trained as a genetic counsellor in Newcastle, Australia in 2002 and then worked for the Victor Chang Cardiac Research Institute with a team that was researching the genetics of heart muscle disease. She then took a job at Newcastle University in the UK on an international clinical trial called the CAPP2 study, combining her interests in genetics and nutrition. This was a large genetically targeted personalised study to find out if aspirin and a dietary supplement called resistant starch could reduce the incidence of bowel cancer and polyps in people that have an inherited risk. Louise also did further training and gained valuable experience as a cancer genetic counsellor in a large NHS genetics unit.

Louise holds the following memberships:
Member of the Human Genetics Society of Australia (HGSA)
Member of the Australasian Society of Genetic Counsellors
New South Wales Oncology Group Cancer Genetics Group
NSW Cancer Institute EviQ Cancer Genetics Reference Committee
Member of InSiGHT (International Society for Gastrointestinal Hereditary Tumours)

Linzi Nolan

DipHE in Ault Nursing, Grad Cert in Oncology Nursing
NELUNE Nurse Unit Manager

 

Linzi is the Nurse Unit Manager for The NELUNE Centre, situated on the ground floor of The Kinghorn Cancer Centre. The NELUNE Centre is an outpatient treatment unit which provides high quality care for people with oncology and haematology disorders. Most of our cancer patients who receive chemotherapy are treated in the centre.

Linzi is responsible for the coordination of service provision to patients within the unit. Paramount to her practice is to ensure that both staff and patients are part of a safe and secure environment. Throughout her professional life Linzi endeavours to maintain a high standard of conduct within the unit that reflects the mission and values of The Sisters of Charity and she encourages her staff to do the same.

Linzi has been responsible for successfully leading and directing the Improved Patient and Staff Experience Project in the unit, which resulted in many positive changes to practice. Linzi is also proactive in Human Resource Management related tasks, such as identifying current and future skill mix for rostering requirements and ensuring compliance with Human Resource policies and directives to ensure the highest standards of care are maintained. Linzi has a strong interest in Human Resources and change management and has been responsible for driving change when processes were examined in preparation for the move into The Kinghorn Cancer Centre.

Background

Linzi studied nursing at The University of Leeds, England, where she gained her Diploma in Higher Education in Adult Nursing. Linzi then went on to work in Haematology and BMT as a Registered Nurse at St James University Hospital, England. In 2004, Linzi relocated to Sydney to work at St Vincent’s Hospital. Linzi completed Haematology & Haemopoietic Cell Transplantation, through distance education with The College of Nursing, in 2007. Linzi then completed her Graduate Certificate in Cancer Nursing from The College of Nursing in 2008.

Beginning her career as a Registered Nurse, Linzi went on to progress to Clinical Nurse Specialist, before being provided the opportunity to work as a Clinical Nurse Consultant in Haematology and Oncology. Since April 2011 Linzi has been the Nurse Unit Manager for The NELUNE Centre. She has worked in a number of roles within the Haematology, BMT and Oncology units, both in the United Kingdom and Australia for over 11 years.

Colette Dolan

RGN, RSCN, Diploma in Government NSW Clinical Redesign, Diploma in Project Management NSW Clinical Redesign, Diploma in Management & Industrial Relations
TKCC Building Services Manager & Cancer Systems Innovation Manager

 

Colette’s role as Building Services Manager & Cancer Systems Innovation Manager for The Kinghorn Cancer Centre involves the planning, coordination and implementation of the occupation of the St Vincent’s dedicated and shared spaces in the Centre. Colette works collaboratively with staff from the Garvan Institute to ensure the delivery of a high quality cancer centre.

Over the pasted 12 months she has been working on policy and procedures in the clinical setting, through patient journeys and facilitated working parties, she has process mapped current practices and established new models of care for the Centre’s clinical areas.

Background

Colette began her nursing training in Ireland and trained as a Sick Children’s Nurse, before becoming a Registered Nurse. She soon found her passion was in management and in motivating staff and producing high quality care for patients. Colette honed these skills by completing a Management and Industrial Relation Diploma at the National College of Industrial Relations, Ireland.

In 2000 Colette relocated to King Faisel Hospital in Riyad, Saudi Arabia where as a Nurse Manager she improved the quality of care for the oncology and haematology outpatients by leading a number of quality improvement projects. Two such initiatives were the establishment of a pre-assessment clinic for children requiring chemotherapy and the setting up of safe areas for sedating paediatric oncology patients requiring painful procedures.

After two and a half years in Saudi Arabia, Colette moved to Australia where she worked as Nurse Unit Manager in Sydney Children’s Hospital. Colette oversaw the relocation and setting up of two new full-service area within the hospital and established a newly refurbished unit, with minimal disruption to patients and their families.

Colette joined St Vincent’s Haematology Oncology Ambulatory Care Department in 2010 as Nurse Unit Manager. She also successfully completed the New South Wales Diploma in Project Management and Clinical Governance in 2010. She began her current role at TKCC in July 2011.

The Kinghorn Cancer Centre eNews Issue 12 – December 2013

 

Cancer research news from Garvan

Some exciting research by Garvan researchers in the Kinghorn Cancer Centre in 2013 includes:

– Potential treatment for a specific kind of pancreatic cancer: Pancreatic cancer surgeon and Garvan researcher Prof Andrew Biankin and colleagues Drs Angela Chou and Mark Crowley in collaboration with University of Queensland have identified a potentially treatable subtype of pancreatic cancer, which accounts for 2% of new cases. This subtype expresses high levels of the HER2 gene (photo on the left is a tissue sample stained red to highlight the HER2 gene) and HER2-amplified breast and gastric cancers are currently treated with Herceptin.

The new study, published in Genome Medicine, used a combination of modern genetics and traditional pathology to estimate the prevalence of HER2-amplified pancreatic cancer. Herceptin is not currently available for treating HER2-amplified pancreatic cancer as no clinical trial has yet been conducted to determine the drug’s efficacy in that case.

Garvan, in collaboration with The Australasian Gastro-Intestinal Trials Group, is recruiting pancreatic cancer patients through the APGI for a pilot clinical trial, known as ‘IMPaCT’, to test personalised medicine strategies. Potential patients will be screened for specific genetic characteristics, including high levels of HER2, based on their biological material sequenced as part of the Australian Pancreatic Cancer Genome Initiative study.

Read more on this story

– New hope for hormone resistant breast cancer: Garvan’s Dr Andrew Stone, Prof Susan Clark and Prof Liz Musgrove, in collaboration with scientists from Cardiff University, have shown that a specific change, which occurs when tumours become resistant to anti-oestrogen therapy, might make the cancers susceptible to treatment with chemotherapy drugs.

The research team demonstrated that the BCL-2 gene, which is fundamental in keeping cells alive, is epigenetically – a process that makes changes in cells that impact DNA – silenced in oestrogen-resistant tumours. The findings are online in the international journal Molecular Cancer Therapetics. When the BCL-2 gene is silenced, cells become more vulnerable to chemotherapy. This process is potentially detectable in the blood, providing a diagnostic marker.

“The next step will be to test our findings in clinical studies. We propose that if the BCL-2 gene is silenced, patients with oestrogen receptor positive breast cancer would benefit from combination therapy. Tamoxifen could be used in combination with a chemotheraphy drug to kill off vulnerable tumour cells,” said Dr Stone.

Read more on this exciting development

Cancer services/care news from St Vincent’s

Officially opened by Prime Minister Julia Gillard on 28th August 2012, TKCC has since had many high profile visitors, including Governor-General Quentin Bryce, NSW Governor Prof Maria Bashir and previous Health Minister Tanya Plibersek. Much has been achieved since the opening to establish a fully operational centre including the relocation of most of Garvan’s cancer labs and some of St Vincent’s cancer care services; as well as installation of next generation, state-of-the-art gene sequencing equipment.

On the clinical side, those staff and services chosen to move from St Vincent’s Hospital to TKCC in Phase 1, such as chemotherapy and outpatient facilities, medical, nursing, allied health and clinical trial and cancer registry staff, were settled in by April 2013. The first year has seen TKCC treat some 15,000 patients, many of whom have provided their feedback via a formal survey process, the results of which have been highly positive in all facets. The quality of the environment and the care provided have all been highly rated by patients, which will be of no surprise to anyone who has entered the building.

Going forward patients will also have access to additional allied health services such as nutritional experts, massage therapists and acupuncture, with the future opening of the Wellness Centre.

Read more on the progress that’s been made at TKCC

In recognition of the great research and clinical care given at TKCC, the Government announced in May this year a $5.5 million boost over 4 years to TKCC’s National Prostate Cancer Research Centre.

“This injection of funds is tremendous news for men affected by, and at risk of, prostate cancer, which is the second most common cause of cancer deaths in Australia and which takes the lives of over 3,000 men every year,” said Prof Allan Spigelman, Acting Director, The Kinghorn Cancer Centre.

Click here for more information on what this funding will mean for TKCC

Celebrating 1 year anniversary of The Kinghorn Cancer Centre

Garvan and St Vincent’s Hospital staff came together in the John Shine Room in September to celebrate the first anniversary of The Kinghorn Cancer Centre (TKCC). Sister of Charity Anthea Groves (right in picture) reflected on the importance of TKCC to the mission of the sisters and provided a blessing.

Acting Director and Clinical Director Prof Allan Spigelman (left in picture) spoke about the creation of the joint facility and shared positive feedback from patients, while Head of Garvan’s Cancer Research Program, Prof Sue Clark (center in picture), took the opportunity to reflect on the significant contribution of the late Prof Rob Sutherland in the creation of the Centre and its vision.

Click here to read the full story